智通财经APP获悉，生物技术公司Anavex Life Sciences(AVXL.US)周一股价收涨30%，此前该公司发布了第三季度财报，并宣布欧盟监管机构已接受其阿尔茨海默病候选药物blarcamesine的上市申请。
该公司表示，欧洲药品管理局已经接受了其早期阿尔茨海默病口服治疗药物blarcamesine的申请。
Anavex表示，该药的安全性表明它不需要核磁共振成像(MRI)监测。鉴于其不同的作用机制，blarcamesine 可以为注射用抗β淀粉样蛋白单克隆抗体药物提供补充或替代治疗。
该公司还报告称，第三财季每股亏损扩大至0.14美元，且没有营收，而2023年同期为每股净亏损0.12美元，没有营收。分析师平均预计每股亏损为0.16 美元，营收为零。
Anavex补充说，截至9月底，公司拥有1.322亿美元的现金和等价物，可提供约四年的现金储备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.